Translating the Research in Insulin Injection Technique: Implications for Practice

Diabetes Educator

Volumn 38, Issue 5, 2012, Pages 635-643

  Saltiel Berzin, Rita ^a   Cypress, Marjorie ^b   Gibney, Michael ^a  

^a BD Technologies   (United States)

^b ABQ Health Partners   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

BODY MASS; CHECKLIST; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; HUMAN; PATIENT EDUCATION; REVIEW; SELF CARE; TRANSLATIONAL RESEARCH;

BODY MASS INDEX; CHECKLIST; DIABETES MELLITUS; EVIDENCE-BASED PRACTICE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PATIENT EDUCATION AS TOPIC; SELF CARE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84871710133     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721712455107     Document Type: Article

References (42)

1. Dutch Association for Nurses in Diabetes. The Administration of Insulin With the Insulin Pen. Utrecht, Netherlands: EADV; 2008.
2. De Coninck C, Frid A, Gaspar R. Results and analysis of the 2008-2009 insulin injection technique questionnaire survey. J Diabetes. 2010;2:168-179.
3. Frid A, Hirsch L, Gaspar R. New injection recommendations for patients with diabetes. Diabetes Metab. 2010:36:S3-S18.
4. Pitel M. The subcutaneous injection. Am J Nurs. 1971:71:76-79.
5. Gibney MA, Arce CH, Byron KJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010;26:1519-1530.
6. Schwartz S, Hassman D, Shelmet J. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26:1663-1678.
7. Kreugel G, Keers JC, Kerstens MN, Wolffenbuttel BHR. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diab Tech Ther. 2011;13(7):737-741.
8. Hirsch LJ, Klaff LJ, Bailey TS. Comparative glycemic control, safety and patient ratings for a new 4 mm x 32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010;26:1531-1541.
9. Birkebaek NH, Solvig J, Hansen B. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diab Care 2008;31:e65.
10. Seidenari S, Giusti G, Bertoni L. Thickness and echogenicity of the skin in children as assessed by 20-MHz ultrasound. Dermatology. 2000;201:218-222.
11. Hofman PL, Lawton SA, Peart JM. An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diabet Med 2007;24:1400-1405.
12. Frid A, Östman J, Linde B., Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care. 1990;13:473-477.
13. Frid A, Linden B., Computed Tomography of Injection Sites in Patients With Diabetes Mellitus: Injection and Absorption of Insulin [thesis]. Stockholm, Sweden; 1992.
14. Bantle JP, Neal L, Frankamp LM., Effect of the anatomical region used for insulin injections on glycemia in type 1 diabetes subjects. Diabetes Care. 1993;16(12):1592-1597.
15. Mudaliar SR, Lindberg FA, Joyce M. Insulin aspart (B28 asp-insulin): a fast acing analog of human insulin. Diabetes Care. 1999;22:1501-1506.
16. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R., Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men. Diabetes Care. 2000;23:813-819.
17. Peter R, Luzio SD, Dunseath G. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2005;28:560-565.
18. Wittmann A, Kover J, Kralj N. Insulin leakage value in relation to pen needle length and administered dose after subcutaneous injection. Diab Tech Ther. 2010;12(8):587-590.
19. Young R, Hannan WJ, Frier BM. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984;7:479-480.
20. Chowdhury TA, Escudier V., Poor glycaemic control caused by insulin induced lipohypertrophy. BMJ. 2003;327:383-384.
21. Gentile S, Agrusta M, Guarino G. Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol. 2011;48:121-125.
22. de Villiers FPR. Lipohypertrophy: a complication of insulin injections. So African Med J. 2005;95:858-859.
23. Vardar B, Kizilci S., Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diab Res Clin Pract. 2007;77:231-236.
24. Hauner H, Stockamp B, Haastert B., Prevalence of lipohypertrophy in insulin treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diab. 1996;104:106-110.
25. Johansson UB, Amsberg S, Hannerz L. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care. 2005;28(8):2025-2027.
26. Overland J, Molyneaux L, Tewari S. Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system. Diab Obes Metab. 2009;11:460-463.
27. Jehle PM, Micheler C, Jehle DR. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet. 1999;354:1604-1607.
28. Kaiser P, Maxeiner S, Werise A. Assessment of the mixing efficiency of neutral protamine hagedon cartridges. J Diab Sci Technol. 2010;4:652-657.
29. Brown A, Steel JM, Duncan D. As assessment of the adequacy of suspension of insulin in pen injectors. Diabet Med. 2004; 21:604-608.
30. Fleming DR, Jacober SJ, Vandenberg MA, Fitzgerald JT, Grunberger G., The safety of injecting insulin through clothing. Diabetes Care. 1997;20:244-247.
31. Koivisto VA, Felig P., Is skin preparation necessary before insulin injection? Lancet. 1978:20:1072-1075.
32. Borders LM, Bingham PR, Riddle MC., Traditional insulin-use practices and the incidence of bacterial contamination and infection. Diabetes Care. 1984:7:121-127.
33. Bruttomesso D, Costa S, Dal Pos M. Educating diabetic patients about insulin use: changes over time in certainty and correctness of knowledge. Diabetes Metab. 2006;32:256-261.
34. Scain SF, Friedman R, Gros JL., A structured educational program improves metabolic control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Educ. 2009;35:603-611.
35. Takahashi Y, Hosokawa M, Yamauchi M., Reeducation of insulin injection decreased the dosage of insulin injection in diabetic patients. Paper presented at: 68th Scientific Sessions of the American Diabetes Association; June 2008; San Francisco, CA.
36. Matsumura M, Monden T, Nakatani Y. Improvement of glycemic control by reeducation in insulin injection technique. Diabetes. 2007;56:S1.
37. Karter AJ, Subramanian U, Saha C. Barriers to insulin initiation: the Translating Research Into Action for Diabetes Insulin Starts Project. Diabetes Care. 2010;33:733-735.
38. Schillinger D, Piette J, Grumbach K. Closing the loop: physician communication with diabetic patients who have low health literacy. Arch Intern Med. 2003;163:83-90.
39. American Association of Diabetes Educators. Injection Impact Report [survey]. http://www.injectionimpact.com/. Published 2008.
40. Cramer JA., A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:2284.
41. Rubin RR., Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Amer J Med. 2005:118:27S-34S.
42. Rubin R, Peyrot M., Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31:430-432.